Clinical Trial Update: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TRK-950 in combination with ramucirumab and paclitaxel for gastric cancer in recruiting status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)
• TRK-950

Snippet

Sponsor: Toray Industries, Inc | Conditions: Gastric Adenocarcinoma, Gastric Cancer | Phase 2 | Status: RECRUITING